ReviewF1000Research2016
Epidemiology, virulence factors and management of the pneumococcus.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- The diagnosis of aspiration pneumonia in older persons: a systematic review.European geriatric medicine · 2022Pooled it
- Pediatric Pneumococcal Eye Infection and Changes in Antibiotic Susceptibility: A Retrospective Study.Infection & chemotherapy · 2026Article
- Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review.Infection and drug resistance · 2025Review
- Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study.Human vaccines & immunotherapeutics · 2024Article
- Vaccination coverage in Italian children and antimicrobial resistance: an ecological analysis.Antimicrobial resistance and infection control · 2022Article
- Pneumonia, Aspiration Pneumonia, or Frailty-Associated Pneumonia?Geriatrics (Basel, Switzerland) · 2022Article
- Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice.Scientific reports · 2022Article
- A Paradigm Shift in the Diagnosis of Aspiration Pneumonia in Older Adults.Journal of clinical medicine · 2022Article
- Gram-Positive Pneumonia: Possibilities Offered by Phage Therapy.Antibiotics (Basel, Switzerland) · 2021Review
- Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens.Microorganisms · 2021Review
- Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Article
- The impact of human vaccines on bacterial antimicrobial resistance. A review.Environmental chemistry letters · 2021Review
- A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.Human vaccines & immunotherapeutics · 2020Article
- TheApplied and environmental microbiology · 2020Article
- Article
- Streptococcal Serine-Rich Repeat Proteins in Colonization and Disease.Frontiers in microbiology · 2020Review
- Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia.Journal of clinical medicine · 2019Article
- Draft Genome Sequences of Two Streptococcus pneumoniae Strains Causing Invasive Infections in Children in Qatar.Microbiology resource announcements · 2019Article
- Streptococcus pneumoniae Cell Wall-Localized Trigger Factor Elicits a Protective Immune Response and Contributes to Bacterial Adhesion to the Host.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal infections continue to cause significant morbidity and mortality in patients throughout the world. This microorganism remains the most common bacterial cause of community-acquired pneumonia and is associated with a considerable burden of disease and health-care costs in both developed and developing countries. Emerging antibiotic resistance has been a concern because of its potential negative impact on the outcome of patients who receive standard antibiotic therapy. However, there have been substantial changes in the epidemiology of this pathogen in recent years, not least of which has been due to the use of pneumococcal conjugate vaccines in children, with subsequent herd protection in unvaccinated adults and children. Furthermore, much recent research has led to a better understanding of the virulence factors of this pathogen and their role in the pathogenesis of severe pneumococcal disease, including the cardiac complications, as well as the potential role of adjunctive therapy in the management of severely ill cases. This review will describe recent advances in our understanding of the epidemiology, virulence factors, and management of pneumococcal community-acquired pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.